Barely Significant
← all excerpts

Placebo-controlled Phase 2 Trial of Drisapersen for Duchenne Muscular Dystrophy.

Ann Clin Transl Neurol · 2018 · PMC6093847 · PMID 30128316

Europe PMCDOI
1
hedged sentence
0.0690
closest p · 1.4× alpha
0.0690
boldest claim

The sentences

showed a trendP = 0.069so close (0.05 < p ≤ 0.1)
The results showed a trend ( P = 0.069) in favor for drisapersen 6 mg/kg/week.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.